FDA Pulls Ranitidine Drugs (Zantac) Off Market Because of Cancer Risk
Effective April 1, 2020, the Food and Drug Administration (FDA) requested the removal of ranitidine products (Zantac) from the market. These popular over-the-counter products have been used as an antacid for reflux and other intestinal conditions for decades.
The FDA said:
“[I]t is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac).”
For further information, see the announcement here.
If you or a loved one have used these products in the past and have been diagnosed with cancer, contact the lawyers at Grossman Green PLLC to evaluate whether you may have a potential case.
